# Study to Evaluate IMG-004 in Healthy Participants

> **NCT05349097** · PHASE1 · COMPLETED · sponsor: **Inmagene LLC** · enrollment: 72 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** SAD IMG-004 30mg
- **DRUG:** SAD IMG-004 100mg
- **DRUG:** SAD IMG-004 200mg
- **DRUG:** SAD IMG-004 400mg
- **DRUG:** SAD IMG-004 600mg
- **DRUG:** SAD Placebo 30mg
- **DRUG:** SAD Placebo 100mg
- **DRUG:** SAD Placebo 200mg
- **DRUG:** SAD Placebo 400mg
- **DRUG:** SAD Placebo 600mg
- **DRUG:** MAD IMG-004 50mg
- **DRUG:** MAD Placebo 50mg
- **DRUG:** MAD IMG-004 150mg
- **DRUG:** MAD Placebo 150mg
- **DRUG:** MAD IMG-004 300mg
- **DRUG:** MAD Placebo 300mg
- **DRUG:** FE IMG-004 150mg

## Key facts

- **NCT ID:** NCT05349097
- **Lead sponsor:** Inmagene LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-08
- **Primary completion:** 2024-05-02
- **Final completion:** 2024-05-02
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05349097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05349097, "Study to Evaluate IMG-004 in Healthy Participants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05349097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*